Martin, M. J., Eberlein, C., Taylor, M., Ashton, S., Robinson, D., & Cross, D. (2016). Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. Oncotarget.

Martin, Matthew J., Cath Eberlein, Molly Taylor, Susan Ashton, David Robinson, and Darren Cross. "Inhibition of Oxidative Phosphorylation Suppresses the Development of Osimertinib Resistance in a Preclinical Model of EGFR-driven Lung Adenocarcinoma." Oncotarget 2016.

Martin, Matthew J., et al. "Inhibition of Oxidative Phosphorylation Suppresses the Development of Osimertinib Resistance in a Preclinical Model of EGFR-driven Lung Adenocarcinoma." Oncotarget 2016.